Identification and validation of leucine-rich α-2-glycoprotein 1 as a noninvasive biomarker for improved precision in prostate cancer risk stratification
<p><strong>Background:</strong><br /> More accurate risk assessments are needed to improve prostate cancer management.</p><br /> <p><strong>Objective:</strong><br /> To identify blood-based protein biomarkers that provided prognostic infor...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2020
|
| _version_ | 1797101381713133568 |
|---|---|
| author | Guldvik, IJ Zuber, V Braadland, PR Grytli, HH Ramberg, H Lilleby, W Thiede, B Zucknick, M Saatcioglu, F Gislefoss, R Kvåle, R George, A Grönberg, H Wiklund, F Neal, DE Gnanapragasam, VJ Taskén, KA Mills, IG |
| author_facet | Guldvik, IJ Zuber, V Braadland, PR Grytli, HH Ramberg, H Lilleby, W Thiede, B Zucknick, M Saatcioglu, F Gislefoss, R Kvåle, R George, A Grönberg, H Wiklund, F Neal, DE Gnanapragasam, VJ Taskén, KA Mills, IG |
| author_sort | Guldvik, IJ |
| collection | OXFORD |
| description | <p><strong>Background:</strong><br />
More accurate risk assessments are needed to improve prostate cancer management.</p><br />
<p><strong>Objective:</strong><br />
To identify blood-based protein biomarkers that provided prognostic information for risk stratification.</p><br />
<p><strong>Design, Setting, and Participants:</strong><br />
Mass spectrometry was used to identify biomarker candidates from blood, and validation studies were performed in four independent cohorts retrospectively collected between 1988 and 2015.</p><br />
<p><strong>Outcome Measurements and Statistical Analysis:</strong><br />
The primary outcome objectives were progression-free survival, prostate cancer–specific survival (PCSS), and overall survival. Statistical analyses to assess survival and model performance were performed.</p><br />
<p><strong>Results and Limitation:</strong><br />
Serum leucine-rich α-2-glycoprotein 1 (LRG1) was found to be elevated in fatal prostate cancer. LRG1 provided prognostic information independent of metastasis and increased the accuracy in predicting PCSS, particularly in the first 3 yr. A high LRG1 level is associated with an average of two-fold higher risk of disease-progression and mortality in both high-risk and metastatic patients. However, our study design, with a retrospective analysis of samples spanning several decades back, limits the assessment of the clinical utility of LRG1 in today’s clinical practice. Thus, independent prospective studies are needed to establish LRG1 as a clinically useful biomarker for patient management.</p><br />
<p><strong>Conclusions:</strong><br />
High blood levels of LRG1 are unfavourable in newly diagnosed high-risk and metastatic prostate cancer, and LRG1 increased the accuracy of risk stratification of prostate cancer patients.</p><br />
<p><strong>Patient Summary:</strong><br />
High blood levels of leucine-rich α-2-glycoprotein 1 are unfavourable in newly diagnosed high-risk and metastatic prostate cancer.</p>
|
| first_indexed | 2024-03-07T05:51:05Z |
| format | Journal article |
| id | oxford-uuid:e8e889a7-3ba0-4a65-ba17-e02f617c8684 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:51:05Z |
| publishDate | 2020 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:e8e889a7-3ba0-4a65-ba17-e02f617c86842022-03-27T10:50:21ZIdentification and validation of leucine-rich α-2-glycoprotein 1 as a noninvasive biomarker for improved precision in prostate cancer risk stratificationJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:e8e889a7-3ba0-4a65-ba17-e02f617c8684EnglishSymplectic ElementsElsevier2020Guldvik, IJZuber, VBraadland, PRGrytli, HHRamberg, HLilleby, WThiede, BZucknick, MSaatcioglu, FGislefoss, RKvåle, RGeorge, AGrönberg, HWiklund, FNeal, DEGnanapragasam, VJTaskén, KAMills, IG<p><strong>Background:</strong><br /> More accurate risk assessments are needed to improve prostate cancer management.</p><br /> <p><strong>Objective:</strong><br /> To identify blood-based protein biomarkers that provided prognostic information for risk stratification.</p><br /> <p><strong>Design, Setting, and Participants:</strong><br /> Mass spectrometry was used to identify biomarker candidates from blood, and validation studies were performed in four independent cohorts retrospectively collected between 1988 and 2015.</p><br /> <p><strong>Outcome Measurements and Statistical Analysis:</strong><br /> The primary outcome objectives were progression-free survival, prostate cancer–specific survival (PCSS), and overall survival. Statistical analyses to assess survival and model performance were performed.</p><br /> <p><strong>Results and Limitation:</strong><br /> Serum leucine-rich α-2-glycoprotein 1 (LRG1) was found to be elevated in fatal prostate cancer. LRG1 provided prognostic information independent of metastasis and increased the accuracy in predicting PCSS, particularly in the first 3 yr. A high LRG1 level is associated with an average of two-fold higher risk of disease-progression and mortality in both high-risk and metastatic patients. However, our study design, with a retrospective analysis of samples spanning several decades back, limits the assessment of the clinical utility of LRG1 in today’s clinical practice. Thus, independent prospective studies are needed to establish LRG1 as a clinically useful biomarker for patient management.</p><br /> <p><strong>Conclusions:</strong><br /> High blood levels of LRG1 are unfavourable in newly diagnosed high-risk and metastatic prostate cancer, and LRG1 increased the accuracy of risk stratification of prostate cancer patients.</p><br /> <p><strong>Patient Summary:</strong><br /> High blood levels of leucine-rich α-2-glycoprotein 1 are unfavourable in newly diagnosed high-risk and metastatic prostate cancer.</p> |
| spellingShingle | Guldvik, IJ Zuber, V Braadland, PR Grytli, HH Ramberg, H Lilleby, W Thiede, B Zucknick, M Saatcioglu, F Gislefoss, R Kvåle, R George, A Grönberg, H Wiklund, F Neal, DE Gnanapragasam, VJ Taskén, KA Mills, IG Identification and validation of leucine-rich α-2-glycoprotein 1 as a noninvasive biomarker for improved precision in prostate cancer risk stratification |
| title | Identification and validation of leucine-rich α-2-glycoprotein 1 as a noninvasive biomarker for improved precision in prostate cancer risk stratification |
| title_full | Identification and validation of leucine-rich α-2-glycoprotein 1 as a noninvasive biomarker for improved precision in prostate cancer risk stratification |
| title_fullStr | Identification and validation of leucine-rich α-2-glycoprotein 1 as a noninvasive biomarker for improved precision in prostate cancer risk stratification |
| title_full_unstemmed | Identification and validation of leucine-rich α-2-glycoprotein 1 as a noninvasive biomarker for improved precision in prostate cancer risk stratification |
| title_short | Identification and validation of leucine-rich α-2-glycoprotein 1 as a noninvasive biomarker for improved precision in prostate cancer risk stratification |
| title_sort | identification and validation of leucine rich α 2 glycoprotein 1 as a noninvasive biomarker for improved precision in prostate cancer risk stratification |
| work_keys_str_mv | AT guldvikij identificationandvalidationofleucinericha2glycoprotein1asanoninvasivebiomarkerforimprovedprecisioninprostatecancerriskstratification AT zuberv identificationandvalidationofleucinericha2glycoprotein1asanoninvasivebiomarkerforimprovedprecisioninprostatecancerriskstratification AT braadlandpr identificationandvalidationofleucinericha2glycoprotein1asanoninvasivebiomarkerforimprovedprecisioninprostatecancerriskstratification AT grytlihh identificationandvalidationofleucinericha2glycoprotein1asanoninvasivebiomarkerforimprovedprecisioninprostatecancerriskstratification AT rambergh identificationandvalidationofleucinericha2glycoprotein1asanoninvasivebiomarkerforimprovedprecisioninprostatecancerriskstratification AT lillebyw identificationandvalidationofleucinericha2glycoprotein1asanoninvasivebiomarkerforimprovedprecisioninprostatecancerriskstratification AT thiedeb identificationandvalidationofleucinericha2glycoprotein1asanoninvasivebiomarkerforimprovedprecisioninprostatecancerriskstratification AT zucknickm identificationandvalidationofleucinericha2glycoprotein1asanoninvasivebiomarkerforimprovedprecisioninprostatecancerriskstratification AT saatciogluf identificationandvalidationofleucinericha2glycoprotein1asanoninvasivebiomarkerforimprovedprecisioninprostatecancerriskstratification AT gislefossr identificationandvalidationofleucinericha2glycoprotein1asanoninvasivebiomarkerforimprovedprecisioninprostatecancerriskstratification AT kvaler identificationandvalidationofleucinericha2glycoprotein1asanoninvasivebiomarkerforimprovedprecisioninprostatecancerriskstratification AT georgea identificationandvalidationofleucinericha2glycoprotein1asanoninvasivebiomarkerforimprovedprecisioninprostatecancerriskstratification AT gronbergh identificationandvalidationofleucinericha2glycoprotein1asanoninvasivebiomarkerforimprovedprecisioninprostatecancerriskstratification AT wiklundf identificationandvalidationofleucinericha2glycoprotein1asanoninvasivebiomarkerforimprovedprecisioninprostatecancerriskstratification AT nealde identificationandvalidationofleucinericha2glycoprotein1asanoninvasivebiomarkerforimprovedprecisioninprostatecancerriskstratification AT gnanapragasamvj identificationandvalidationofleucinericha2glycoprotein1asanoninvasivebiomarkerforimprovedprecisioninprostatecancerriskstratification AT taskenka identificationandvalidationofleucinericha2glycoprotein1asanoninvasivebiomarkerforimprovedprecisioninprostatecancerriskstratification AT millsig identificationandvalidationofleucinericha2glycoprotein1asanoninvasivebiomarkerforimprovedprecisioninprostatecancerriskstratification |